IV melphalan may reduce the threshold for BCNU lung toxicity.
Source: NLP:melphalan hydrochloride
Melphalan Hydrochloride Interactions
Brand names: Melphalan Hydrochloride
Route: Intravenous
FDA Black Box Warning
BOXED WARNING Melphalan should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Severe bone marrow suppression with resulting infection or bleeding may occur. Controlled trials comparing intravenous (IV) to oral melphalan have shown more myelosuppression with the IV formulation. Hypersensitivity reactions, including anaphylaxis, have occurred in approximately 2% of patients who received the IV formulation. Melphalan is leukemogenic in humans. Melphalan produces chromosomal aberrations in vitro and in vivo and, therefore, should be considered potentially mutagenic in humans.
Contraindications
CONTRAINDICATIONS Melphalan should not be used in patients whose disease has demonstrated prior resistance to this agent. Patients who have demonstrated hypersensitivity to melphalan should not be given the drug.
Pregnancy & Breastfeeding
PREGNANCY Teratogenic Effects: Pregnancy Category D: See WARNINGS section.
4 interactions on record
Cisplatin may affect melphalan kinetics by inducing renal dysfunction and altering melphalan clearance.
Source: NLP:melphalan hydrochloride
Severe renal failure has been reported when IV melphalan is followed by standard oral doses of cyclosporine.
Source: NLP:melphalan hydrochloride
Simultaneous administration of nalidixic acid and IV melphalan increases the incidence of severe hemorrhagic necrotic enterocolitis in pediatric patients.
Source: NLP:melphalan hydrochloride